Leading regenerative medicine company, Personalized Stem Cells, Inc. (PSC), proudly announces the successful resolution of the ongoing patent litigation by its licensor, VetStem, Inc., with California Stem Cell Treatment Center, Inc. (“CSCTC”). VetStem, Inc. v. California Stem Cell Treatment Center, Inc. Case No. 2:19-CV-4728-AB filed in the Central District of California, Western Division, centered on CSCTC’s alleged infringement of VetStem’s patented treatment methods using adipose-derived stem cells. VetStem’s dedication to innovative research in therapeutic applications of adipose-derived stem cells resulted in the issuance of multiple patents, including U.S. Patent No. 9,453,202, granted by the United States Patent and Trademark Office on September 27, 2016.
VetStem initiated legal action against CSCTC to protect its intellectual property, which is licensed to PSC for use in human medicine. VetStem’s legal action alleged that performance of certain regenerative stem cell procedures by CSCTC infringed upon VetStem’s ‘202 Patent covering regenerative medical treatments for orthopedic conditions. The resolution came on the eve of the trial, with both parties agreeing to a settlement. Dr. Bob Harman, Founder and Chief Executive Officer of VetStem and named inventor of the ‘202 Patent, expressed his satisfaction with the settlement, stating, “VetStem is committed to the development of innovative stem cell treatments and technology, and to protecting and enforcing our intellectual property rights.” VetStem offers licensing deals with leading companies and doctors in the field of regenerative medicine to rapidly advance treatments to patients.
VetStem is a prominent veterinary company specializing in research and development of regenerative medicine therapies. VetStem’s impact extends beyond veterinary applications, as demonstrated by its subsidiary, Personalized Stem Cells. Dedicated to advancing regenerative stem cell therapies for serious human diseases, PSC has achieved rapid clinical trial results from its Phase 2a study focusing on human autologous stem cell therapy for knee osteoarthritis, as well as a Phase 1b intravenous clinical study of human mesenchymal stem cells (COVI-MSC™) for COVID-19 patients. PSC’s rapid progress into clinical applications is facilitated by leveraging VetStem’s extensive database of disease treatments in animals, showcasing an innovative approach that holds promise for transformative developments in regenerative medicine for both humans and animals.